References
- KandothCMcLellanMDVandinFMutational landscape and significance across 12 major cancer typesNature2013502747133333924132290
- KimMPZhangYLozanoGMutant p53: multiple mechanisms define biologic activity in cancerFront Oncol2015524926618142
- DumayAFeugeasJPWittmerEDistinct tumor protein p53 mutants in breast cancer subgroupsInt J Cancer201313251227123122886769
- ForbesSABindalNBamfordSCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Res201139DD945D95020952405
- MalkinDLi-Fraumeni syndromeGenes Cancer20112447548421779515
- MullerPAVousdenKHMutant p53 in cancer: new functions and therapeutic opportunitiesCancer Cell201425330431724651012
- SabapathyKThe contrived mutant p53 oncogene: beyond loss of functionsFront Oncol2015527626697411
- KimMPLozanoGMutant p53 partners in crimeCell Death Differ201825116116829099488
- OliveKPTuvesonDARuheZCMutant p53 gain of function in two mouse models of Li-Fraumeni syndromeCell2004119684786015607980
- HanelWMarchenkoNXuSYuSXWengWMollUTwo hot spot mutant p53 mouse models display differential gain of function in tumorigenesisCell Death Differ201320789890923538418
- Freed-PastorWAPrivesCMutant p53: one name, many proteinsGenes Dev201226121268128622713868
- YueXZhaoYXuYZhengMFengZHuWMutant p53 in cancer: accumulation, gain-of-function, and therapyJ Mol Biol2017429111595160628390900
- Lasagna-ReevesCAClosALCastillo-CarranzaDDual role of p53 amyloid formation in cancer: loss of function and gain of toxicityBiochem Biophys Res Commun2013430396396823261448
- GhoshSSalotSSenguptaSP53 amyloid formation leading to its loss of function: implications in cancer pathogenesisCell Death Differ201724101784179828644435
- SilvaJLCinoEASoaresINFerreiraVFde OliveiraGATargeting the prion-like aggregation of mutant p53 to combat cancerAcc Chem Res201851118119029260852
- MantovaniFWalerychDSalGDTargeting mutant p53 in cancer: a long road to precision therapyFEBS J2017284683785027808469
- WalerychDLisekKdel SalGMutant p53: one, no one, and one hundred thousandFront Oncol2015528926734571
- HauptSRaghuDHauptYMutant p53 drives cancer by subverting multiple tumor suppression pathwaysFront Oncol201661226858938
- ThukralSKLuYBlainGCHarveyTSJacobsenVLDiscrimination of DNA binding sites by mutant p53 proteinsMol Cell Biol1995159519652027651437
- Dell’OrsoSFontemaggiGStambolskyPChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promotersOMICS201115530531221332394
- FontemaggiGDell’OrsoSTrisciuoglioDThe execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesisNat Struct Mol Biol200916101086109319783986
- ValentiFGanciFFontemaggiGGain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expressionOncotarget2015685547556625650659
- Di AgostinoSStranoSEmiliozziVGain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulationCancer Cell200610319120216959611
- LiuKLingSLinWCTopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73Mol Cell Biol201131224464448121930790
- KrishnanSRNairBCSareddyGRNovel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cellsBreast Cancer Res Treat2015150348749925788226
- Di AgostinoSSorrentinoGIngallinaEYAP enhances the pro-proliferative transcriptional activity of mutant p53 proteinsEMBO Rep201617218820126691213
- SorrentinoGRuggeriNSpecchiaVMetabolic control of YAP and TAZ by the mevalonate pathwayNat Cell Biol201416435736624658687
- IngallinaESorrentinoGBertolioRMechanical cues control mutant p53 stability through a mevalonate-RhoA axisNat Cell Biol2018201283529255172
- Freed-PastorWAMizunoHZhaoXMutant p53 disrupts mammary tissue architecture via the mevalonate pathwayCell20121481–224425822265415
- WalerychDLisekKSommaggioRProteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancerNat Cell Biol201618889790927347849
- LisekKCampanerECianiYWalerychDdel SalGMutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cellsOncotarget2018929205082052329755668
- KimGMeriinABGabaiVLThe heat shock transcription factor Hsf1 is downregulated in DNA damage-associated senescence, contributing to the maintenance of senescence phenotypeAging Cell201211461762722510478
- LiDYallowitzAOzogLMarchenkoNA gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stressCell Death Dis20145e119424763051
- StambolskyPTabachYFontemaggiGModulation of the vitamin D3 response by cancer-associated mutant p53Cancer Cell201017327328520227041
- VogiatziFBrandtDTSchneikertJMutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5Proc Natl Acad Sci U S A201611352E8433E844227956623
- MullerPAVousdenKHP53 mutations in cancerNat Cell Biol20131512823263379
- MarinMCJostCABrooksLAA common polymorphism acts as an intragenic modifier of mutant p53 behaviourNat Genet2000251475410802655
- GaiddonCLokshinMAhnJZhangTPrivesCA subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domainMol Cell Biol20012151874188711238924
- BergamaschiDGascoMHillerLP53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosisCancer Cell20033438740212726864
- MartynovaEPozziSBasileVGain-of-function p53 mutants have widespread genomic locations partially overlapping with p63Oncotarget20123213214322361592
- StranoSFontemaggiGCostanzoAPhysical interaction with human tumor-derived p53 mutants inhibits p63 activitiesJ Biol Chem200227721188171882611893750
- MullerPACaswellPTDoyleBMutant p53 drives invasion by promoting integrin recyclingCell200913971327134120064378
- AdornoMCordenonsiMMontagnerMA mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasisCell20091371879819345189
- SuXChakravartiDChoMSTAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAsNature2010467731898699020962848
- GirardiniJENapoliMPiazzaSA Pin1/mutant p53 axis promotes aggressiveness in breast cancerCancer Cell2011201799121741598
- EscollMGarginiRCuadradoAAntonIMWandosellFMutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZOncogene201736253515352728166194
- GarginiREscollMGarciaEGarcia-EscuderoRWandosellFAntonIMWIP drives tumor progression through YAP/TAZ-dependent autonomous cell growthCell Rep20161781962197727851961
- StranoSMunarrizERossiMPhysical and functional interaction between p53 mutants and different isoforms of p73J Biol Chem200027538295032951210884390
- Di ComoCJGaiddonCPrivesCP73 function is inhibited by tumor-derived p53 mutants in mammalian cellsMol Cell Biol1999192143814499891077
- MurphyKLDennisAPRosenJMA gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell modelFASEB J200014142291230211053251
- LiuXSunCJinXGenistein enhances the radiosensitivity of breast cancer cells via G2/M cell cycle arrest and apoptosisMolecules20131811132001321724284485
- HuangLLiALiaoGCurcumol triggers apoptosis of p53 mutant triple-negative human breast cancer MDA-MB 231 cells via activation of p73 and PUMAOncol Lett20171411080108828693277
- KravchenkoJEIlyinskayaGVKomarovPGSmall-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathwayProc Natl Acad Sci U S A2008105176302630718424558
- WeissmuellerSManchadoESaborowskiMMutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signalingCell2014157238239424725405
- SongHHollsteinMXuYP53 gain-of-function cancer mutants induce genetic instability by inactivating ATMNat Cell Biol20079557358017417627
- HanelWMollUMLinks between mutant p53 and genomic instabilityJ Cell Biochem2012113243343922006292
- JongYJLiLHTsouMHChromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutationsCancer Genet Cytogenet20041481556514697642
- KleiviKDiepCBPandisNHeimSTeixeiraMRLotheRATP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomasJ Pathol20052071141916007576
- PfisterNTFominVRegunathKMutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cellsGenes Dev201529121298131526080815
- TolstorukovMYSansamCGLuPSwi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promotersProc Natl Acad Sci U S A201311025101651017023723349
- BellazzoADi MininGCollavinLBlock one, unleash a hundred: mechanisms of DAB2IP inactivation in cancerCell Death Differ2017241152527858941
- Di MininGBellazzoAdal FerroMMutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IPMol Cell201456561762925454946
- ValentinoEBellazzoADi MininGMutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IPProc Natl Acad Sci U S A2017114297623762828667123
- ZhouGWangJZhaoMGain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activationMol Cell201454696097424857548
- YueXZhangCZhaoYGain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progressionGenes Dev201731161641165428947497
- BidHKRobertsRDManchandaPKHoughtonPJRAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasisMol Cancer Ther201312101925193424072884
- Castillo-LluvaSTathamMHJonesRCSUMOylation of the GTPa se Rac1 is required for optimal cell migrationNat Cell Biol201012111078108520935639
- LukashchukNVousdenKHUbiquitination and degradation of mutant p53Mol Cell Biol200727238284829517908790
- HauptYMayaRKazazAOrenMMdm2 promotes the rapid degradation of p53Nature199738766302962999153395
- LiDMarchenkoNDSchulzRFunctional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cellsMol Cancer Res20119557758821478269
- PengYChenLLiCLuWChenJInhibition of MDM2 by hsp90 contributes to mutant p53 stabilizationJ Biol Chem200127644405834059011507088
- WhitesellLSutphinPDPulciniEJMartinezJDCookPHThe physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agentMol Cell Biol1998183151715249488468
- LiDMarchenkoNDMollUMSAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axisCell Death Differ201118121904191321637290
- WiechMOlszewskiMBTracz-GaszewskaZWawrzynowBZyliczMZyliczAMolecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2PLoS One2012712e5142623251530
- YueXZhaoYLiuJBAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and functionElife20154e08401
- YueXZhaoYHuangGA novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesisCell Discov201621603927807478
- ValentiFFaustiFBiagioniFMutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loopCell Cycle201110244330434022134238
- RosenbaumJBaekSHDuttaAThe emergence of the conserved AAA+ ATPases Pontin and Reptin on the signaling landscapeSci Signal20136266mr123482663
- ZhaoYZhangCYueXPontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53Cell Death Differ201522111824183625857266
- ParralesAIwakumaTTargeting oncogenic mutant p53 for cancer therapyFront Oncol2015528826732534
- ZhangSZhouLHongBSmall-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53Cancer Res201575183842385226294215
- AlexandrovaEMYallowitzARLiDImproving survival by exploiting tumour dependence on stabilized mutant p53 for treatmentNature2015523756035235626009011
- RamalingamSGossGRosellRA randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)Ann Oncol20152681741174825997818
- JhaveriKChandarlapatySLakeDA phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerClin Breast Cancer201414315416024512858
- WangZTChenZJJiangGMHistone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cellsCell Signal201628550651526876786
- CampanerERustighiAZanniniAA covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of actionNat Commun201781577228598431
- ParralesARanjanAIyerSVDNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathwayNat Cell Biol201618111233124327775703
- SampathJSunDKiddVJMutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1J Biol Chem200127642393593936711483599
- KollareddyMDimitrovaEVallabhaneniKCRegulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activitiesNat Commun20156738926067754
- DoPMVaranasiLFanSMutant p53 cooperates with ETS2 to promote etoposide resistanceGenes Dev201226883084522508727
- UbertiniVNorelliGd’ArcangeloDMutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonistOncogene201534192493250424998848
- WeiSWangHLuCThe activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteinsJ Biol Chem2014289138947895924554706
- ParralesAThoenenEIwakumaTThe interplay between mutant p53 and the mevalonate pathwayCell Death Differ201825346047029238070